SALVOVAR is project funded by the European Commission under the Horizon program. It is a European multi-disciplinary clinical project meant to improve the management of patients with poor prognostic ovarian cancer after neoadjuvant chemotherapy. It is a pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose and dosing schedule with the SALVage (SALVOVAR) weekly dose-dense regimen in patients with poor prognostic OVARian (SALVOVAR) cancers based on the poor tumor primary chemosensitivity and incomplete debulking surgery.